LymeNet Home LymeNet Home Page LymeNet Flash Discussion LymeNet Support Group Database LymeNet Literature Library LymeNet Legal Resources LymeNet Medical & Scientific Abstract Database LymeNet Newsletter Home Page LymeNet Recommended Books LymeNet Tick Pictures Search The LymeNet Site LymeNet Links LymeNet Frequently Asked Questions About The Lyme Disease Network LymeNet Menu

LymeNet on Facebook

LymeNet on Twitter




The Lyme Disease Network receives a commission from Amazon.com for each purchase originating from this site.

When purchasing from Amazon.com, please
click here first.

Thank you.

LymeNet Flash Discussion
Dedicated to the Bachmann Family

LymeNet needs your help:
LymeNet 2020 fund drive


The Lyme Disease Network is a non-profit organization funded by individual donations.

LymeNet Flash Post New Topic  New Poll  Post A Reply
my profile | directory login | register | search | faq | forum home

  next oldest topic   next newest topic
» LymeNet Flash » Questions and Discussion » Medical Questions » The Quest for new antibiotics

 - UBBFriend: Email this page to someone!    
Author Topic: The Quest for new antibiotics
shazdancer
Frequent Contributor (1K+ posts)
Member # 1436

Icon 1 posted      Profile for shazdancer     Send New Private Message       Edit/Delete Post   Reply With Quote 
The Lancet Infectious Diseases
Volume 7, Issue 1 , January 2007, Pages 68-78

Forum
Anti-infective research and development--problems, challenges, and solutions

John S Bradley, Robert Guidos, Steve Baragona, John G Bartlett, Ethan Rubinstein, George G Zhanel, Michael D Tino, David L Pompliano, Frank Tally, Praveen Tipirneni, Glenn S Tillotson, John H Powers and Glenn S Tillotson

Retrieved online.

This group from IDSA is decrying the fact that many of the big pharmaceuticals are not developing new antibiotics.

quote:
We identified several obstacles to antibiotic development.2 Anti-infective drug products are less profitable than other types of medicines, particularly those for chronic conditions.

Furthermore, once a new antibiotic is finally approved, infectious disease physicians add an additional financial disincentive and urge our general practice colleagues to refrain from using it to help reduce the development of resistance.

As a result, many major pharmaceutical companies have decided to focus their research and development efforts elsewhere, leaving the pipeline in this essential field dangerously dry.

One writer suggested working on better immune-support techniques, better dosing times, and combinations therapy...
quote:
Lack of new antibiotics requires re-evaluating and re-investing in monoclonal antibodies, bacteriophages, probiotics, and ways to augment innate immunity.

With few new antibiotics in the pipeline, perhaps we need to go back and re-evaluate our dosing schedules, durations of treatment, and how and when to use combination therapy to achieve clinical success and prevent resistance from occurring.


Posts: 1558 | From the Berkshires | Registered: Jul 2001  |  IP: Logged | Report this post to a Moderator
Truthfinder
Frequent Contributor (1K+ posts)
Member # 8512

Icon 1 posted      Profile for Truthfinder     Send New Private Message       Edit/Delete Post   Reply With Quote 
Good post.

Well, this does help explain why there's not a lot of research being done on new abx, and why the drug companies aren't particularly interested in the whole chronic Lyme problem, as least from the perspective of creating new abx.

Funny they didn't even mention nano-technology.

What's that other thing called where they use specific, ``genetically engineered'' viruses to kill certain other organisms? Gosh, I can't think of the word!

Tracy

--------------------
Tracy
.... Prayers for the Lyme Community - every day at 6 p.m. Pacific Time and 9 p.m. Eastern Time just take a few moments to say a prayer wherever you are.

Posts: 2966 | From Colorado | Registered: Dec 2005  |  IP: Logged | Report this post to a Moderator
clairenotes
Frequent Contributor (1K+ posts)
Member # 10392

Icon 1 posted      Profile for clairenotes         Edit/Delete Post   Reply With Quote 
Quote:

"With few new antibiotics in the pipeline, perhaps we need to go back and re-evaluate our dosing schedules, durations of treatment, and how and when to use combination therapy to achieve clinical success and prevent resistance from occurring.***"

Yes... the answer may lie in the sequencing.

[ 05. January 2007, 12:16 PM: Message edited by: clairenotes ]

Posts: 1111 | From Colorado | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
Greatcod
Unregistered


Icon 1 posted            Edit/Delete Post   Reply With Quote 
The real deal is that most often antibiotics are used for short periods of time, and that diminishes their bottom line potential. Same for diseases that plague the third world; the victims don't have the money to pay for medicines. No profit, no drug.
A serious weak link in the arguement for the infalibility of market systems.

IP: Logged | Report this post to a Moderator
clairenotes
Frequent Contributor (1K+ posts)
Member # 10392

Icon 1 posted      Profile for clairenotes         Edit/Delete Post   Reply With Quote 
Quote:

"A serious weak link in the arguement for the infalibility of market systems."

Very serious!!

Claire

Posts: 1111 | From Colorado | Registered: Oct 2006  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | LymeNet home page | Privacy Statement

Powered by UBB.classic™ 6.7.3


The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:

The Lyme Disease Network of New Jersey
907 Pebble Creek Court, Pennington, NJ 08534 USA


| Flash Discussion | Support Groups | On-Line Library
Legal Resources | Medical Abstracts | Newsletter | Books
Pictures | Site Search | Links | Help/Questions
About LymeNet | Contact Us

© 1993-2020 The Lyme Disease Network of New Jersey, Inc.
All Rights Reserved.
Use of the LymeNet Site is subject to Terms and Conditions.